Kreuter M, Wuyts WA, Wijsenbeek M, et al. - Researchers performed three post hoc analyses, utilizing data collected in the INPULSIS trials, to see how health-related quality of life (HRQoL) and symptoms in patients suffering from idiopathic pulmonary fibrosis (IPF) were influenced by a reduction in forced vital capacity % predicted, the occurrence of acute exacerbations, as well as by treatment with nintedanib. In these analyses, they included patient-reported outcome (PRO) data from the INPULSIS trials. They examined data from 1,061 patients, including 638 nintedanib and 423 placebo. They identified the link of acute exacerbations with deterioration in HRQoL and worsened symptoms. The evaluation of several PROs revealed a slowing in the deterioration in HRQoL and symptoms following treatment with nintedanib vs placebo in patients with advanced IPF. Higher responsiveness to change in advanced disease was shown by HRQoL measures, and these measures may not have the sensitivity to capture change in patients with less-advanced IPF.